CTIS2024-516207-17-00进行中（未招募）1 期
PhagoDAIR I : A Pilot, Multicenter, Randomized, Non Comparative, Double-Blind Study of Phage Therapy in Patients with Hip or Knee Prosthetic Joint Infection due to Staphylococcus aureus Treated with DAIR and Antibiotic Therapy.
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 29
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male or female = 18 years, Negative pregnancy test, Signing a written informed consent before any study related procedures, Affiliated to a national social security system and / or private health insurance in compliance with the recommendations of National Law in force relating to biomedical research, Staphylococcus aureus monomicrobial knee or hip PJI > 1 month after prosthesis implantation with clinical signs of infection and with indication of DAIR with direct closure (if associated flap, arthrotomy must be sealed), and Suppressive Antibiotics Therapy (SAT), Staphylococcus aureus only in joint fluid within 6 months before randomization or in case of relapse of infection under antibiotics therapy after a DAIR performed within 6 months before pre-inclusion visit, Without preoperative diagnosis of superinfection due to another pathogen if treatment is administered at the end of the DAIR, Without diagnosis of superinfection due to another pathogen identified within 72h after a bacteriological sample performed during a DAIR if treatment is administered 14±2 days after a DAIR., Displaying the susceptibility of the strain to at least one of the phages., Patient with a life expectancy of 2 years and more as determined by the principal investigator, Females of childbearing potential/Sexually active males with partner of childbearing potential: commitment to consistently and correctly use an acceptable effective method of birth control (oral, transdermal, systemic or implant contraception birth control, intrauterine devices, condom) for 1 month after the last study drug administration, Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhea duration at least 12 months)
排除标准
- •Early Staphylococcus aureus Prosthesis Joint infection ( < 1 month after the prosthesis implantation), Medical history which in the opinion of the investigator would mean that the patient is unsuitable for participation in the study, Patient who, in the judgment of the Investigator, is likely to be noncompliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development, Currently in exclusion period from a previous study, Concomitant participation to another interventional clinical trial or previous participation with active drug levels still present, i.e. the last medication intake is less than 4 half-lives ago, Patients who are pregnant or breastfeeding. Patients should not be enrolled if they plan to become pregnant during the treatment period and up to 1 month after the last administration of study drug, Women/Men refusing to use an acceptable effective contraception during 1 month after the last administration of study drug, No possibility of contact in case of emergency, Minors, persons deprived of liberty by judicial or administrative decision, persons receiving psychiatric care and persons admitted to a health or social institution, to adult patient under legal protection or unable to express consent., Other germ found in culture of joint fluid sample, Displaying no susceptibility of the strain to anti-Staphylococcus aureus bacteriophages, Patients with ASA score = 4, Severe sepsis or Septic shock or hemodynamic instability, Patients with an indication to prosthesis replacement or amputation, Immunosuppressed patients, Known allergic reactions to components of phages products, Relapse between DAIR and treatment administration planned 14±2 days after a DAIR
研究者
相似试验
进行中（未招募）
1 期
PhagoDAIR I: A Phase I/II Multicenter, Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Phage Therapy in Patients with Hip or Knee Prosthetic Joint Infection due to Staphylococcus aureus Treated with DAIR and Antibiotic Therapy. - PhagoDAIR Iknee or hip prosthetic joint infection (PJI) due to Staphylococcus aureus, with the indication of DAIR and Suppressive Antibiotics Therapy (SATEUCTR2021-004469-11-FRPHERECYDES PHARMA80
终止
1 期
A Phase 1b/IIa trial to explore the combination of a new drug, PLX-7486, with gemcitabine in patients with advanced cancer (part 1b) and with advanced pancreatic ductal cancer and cancer-related pain (Part IIa)Advanced cancer/ Pancreatic Ductal AdenocarcinomaPancreatic Ductal AdenocarcinomaCancerISRCTN10978180HS Greater Glasgow and Clyde30
尚未招募
1 期
A Study to Evaluate BW-00163 in Subjects with HypertensioHypertensionACTRN12622001430729ARGO BIOPHARMA AUSTRALIA PTY LTD48
已完成
1 期
Intranasal Adenoviral vector COVID-19 vaccine (BBV154) Phase 1 studyCTRI/2021/02/031295Bharat Biotech International Ltd
终止
1 期
A Phase 1, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Topical SM04755 Solution Following Topical Administration to Subjects with Mild to Moderate Plaque PsoriasisPlaque psoriasisACTRN12617001178336Samumed Pacific Pty Ltd13